74030-44-7

Basic information

• Product Name: 1-Nitro-4-[4-(trifluoromethoxy)phenoxy]benzene
• Synonyms: 1-Nitro-4-[4-(trifluoromethoxy)phenoxy]benzene;1-Nitro-4-[4-(Trifluoromethoxy)Phenoxy]Benzene(WXC03675)
• CAS NO: 74030-44-7
• Molecular Formula: C₁₃H₈F₃NO₄
• Molecular Weight: 299.2021296
• Mol File: 74030-44-7.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Nitro-4-[4-(trifluoromethoxy)phenoxy]benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Nitro-4-[4-(trifluoromethoxy)phenoxy]benzene(74030-44-7)
• EPA Substance Registry System: 1-Nitro-4-[4-(trifluoromethoxy)phenoxy]benzene(74030-44-7)

Safety Data

• Hazardous Substances Data: 74030-44-7(Hazardous Substances Data)

Usage

Molecular Structure

1-Nitro-4-[4-(trifluoromethoxy)phenoxy]benzene consists of a nitro group (-NO2) attached to a benzene ring, which also contains a phenoxy group (-O-C6H4-) substituted with a trifluoromethoxy group (-O-CHF2).

Common Uses

It is commonly used as a starting material in the synthesis of various pharmaceuticals and agrochemicals.

Reactivity

1-Nitro-4-[4-(trifluoromethoxy)phenoxy]benzene is known for its high reactivity and can be converted into different derivatives through various chemical reactions.

Utilization

It is utilized in the development of new materials and as a reagent in organic chemistry.

Handling Precautions

It may pose health risks if not handled properly, so it is important to handle this chemical with caution.

Upstream product

• 828-27-3 4-Trifluoromethoxyphenol 
• 350-46-9 4-Fluoronitrobenzene 
• 139301-27-2 4-trifluoromethoxyphenylboronic acid 

Downstream Products

• 58119-51-0 4-[4-(trifluoromethoxy)phenoxy]aniline 
• 220616-47-7 4-(4'-trifluoromethoxyphenoxy)-benzenethiol 
• 361547-22-0 methyl (4-(4-trifluoromethoxyphenoxy)phenylsulfanyl)acetate 
• 361547-21-9 dithiocarbonic acid O-ethyl ester S-(4-(4-trifluoromethoxyphenoxy)phenyl) ester 
• 396131-74-1 2-oxo-3-(4-(4-trifluoromethoxyphenoxy)phenylsulfanyl)propane-1-sulfonic acid dimethyl amide 
• 396131-78-5 2-hydroxy-3-(4-(4-trifluoromethoxyphenoxy)phenylsulfanyl)propane-1-sulfonic acid dimethyl amide 
• 396131-75-2 2-hydroxy-3-(4-(4-trifluoromethoxyphenoxy)phenylsulfonyl)propane-1-sulfonic acid dimethyl amide 
• 396131-79-6 2-hydroxyamino-3-(4-(4-trifluoromethoxyphenoxy)phenylsulfonyl)propane-1-sulfonic acid dimethyl amide 
• 1026803-22-4 1-methyl-3-[2-oxo-3-(4-(4-trifluoromethoxyphenoxy)phenylsulfanyl)propyl]-1H-pyrimidine-2,4-dione 
• 1025873-21-5 5,5-dimethyl-3-{2-oxo-3-[4-(4-trifluoromethoxy-phenoxy)-phenylsulfanyl]-propyl}-imidazolidine-2,4-dione 
• 1026147-64-7 1,5,5-trimethyl-3-{2-oxo-3-[4-(4-trifluoromethoxy-phenoxy)-phenylsulfanyl]-propyl}-imidazolidine-2,4-dione 
• 1026484-23-0 1-(4-morpholinylsulfonyl)-3-({4-[4-(trifluoromethoxy)phenoxy]phenyl}sulfanyl)acetone 

Relevant articles and documents

Synthesis and Structure-Activity Relationships for Extended Side Chain Analogues of the Antitubercular Drug (6 S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5 H -imidazo[2,1- b ][1,3]oxazine (PA-824)

Novel extended side chain nitroimidazooxazine analogues featuring diverse linker groups between two aryl rings were studied as a potential strategy to improve solubility and oral activity against chronic infection by Mycobacterium tuberculosis. Both lipop

PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS

The present disclosure provides substituted pyrimidine carboxamides of Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein A1, X, A2, W1, W2, W3, E, Z, and R4 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present disclosure are especially useful for treating pain.

PYRIMIDINES AS SODIUM CHANNEL BLOCKERS

The present disclosure provides substituted pyrimidine compounds of Formula (I), and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein A1, X, A2, W1, W2, W3, E, Z, and R4 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present disclosure are especially useful for treating pain.